The U.S. Food and Drug Administration issued emergency use authorization for Regeneron Pharmaceuticals Inc.’s Covid-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.
AstraZeneca started late-stage trials of an experimental long-acting monoclonal antibody combination drug the company hopes could be used as a so-called prophylactic to prevent Covid-19 infection in at-risk people for up to 12 months.
Regeneron Pharmaceuticals received a $450 million contract to manufacture and supply a two-antibody cocktail for the treatment and prevention of COVID-19 as part of Operation Warp Speed from the Biomedical Advanced Research and Development Authority (BARDA).
Regeneron Pharmaceuticals – with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) – is launching Phase III trials of REGN-COV2, the company’s two-antibody cocktail for the treatment and prevention of COVID-19.
BioSpace reviews some of the more interesting scientific studies recently published, including a Phase II clinical trial out of Hong Kong that found a three drug-antiviral cocktail significantly decreased median time to a negative SARS-CoV-2 test compared to controls.
A review of some recently published scientific studies, including researchers at the University of Maryland Baltimore County identifying a single nucleotide that controls two forms of the HIV virus’ RNA.
A cheaper HIV prevention pill is going on sale in the United States, but experts say the price drop will not help as many people if doctors instead prescribe a newer, more expensive brand-name drug.
Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labelled unprecedented.